Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)?

REFERENCES

• Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472–480.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New Engl J Med 2001;344(14):1052–1056.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay J-Y, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–1134.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma Guidelines. V.2.2007. Available from: http://www.globalgist.org/docs/NCCN-guidelines.pdf. Last accessed 2015 May 1.
   Google Scholar
• Casali PG, Blay J-Y. On behalf of the ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Supplement 5):v98–v102.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Imatinib for the Treatment of Unresectable and/or Metastatic Gastro-Intestinal Stromal Tumours. 2010. NICE Technology Appraisal Guidance 86. Available from: http://www.nice.org.uk/guidance/ta209. Last accessed 2015 May 1.
   Google Scholar
• Reid R, O'Dywer P, MacDuff E, White J, Cowie F, Currie D, Wall L, Niblock P, Walsh S. Guidelines for the Management of Gastrointestinal Stromal Tumours (GIST) in Scotland, Glasgow. Scottish Sarcoma Network; 2009. Available at: http://www.imaginenetwork.scot.nhs.uk/wp-content/2010/ 02/scottish_GIST_guidelines_NOV54S_no-code_041209.pdf. Last accessed 2015 May 1.
   Google Scholar
• Kearon C, Ginsberg JS, Douketis J, Crowther M, Brill-Edwards P, Weitz JI, Hirsch J. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. Ann Intern Med 2001;135(2):108–111.
   PubMed Web of Science ®Google Scholar
• Knowlson L, Bacchu S, Paneesha S, McManus A, Randall K, Rose P. Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J Clin Pathol 2010;63(9):818–822.
   PubMed Web of Science ®Google Scholar
• Newsham AC, Johnston C, Hall G, Leahy MG, Smith AB, Vikram A, Donnelly AM, Velikova G, Selby PJ, Fisher SE. Development of an advanced database for clinical trials integrated with an electronic patient record system. Comput Biol Med 2011;41(8):575–586.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens–a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999;17(1):150–157.
   PubMed Web of Science ®Google Scholar
• Call JW, Walentas CD, Eickhoff JC, Scherzer NJ. Survival of gastrointestinal stromal tumor patients in the Imatinib era: life raft group observational registry. BMC Cancer 2012;12(1):90.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc 1972;34(2):187–220.
   Google Scholar
• Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol 2008;26(24):3913–3915.
   PubMed Web of Science ®Google Scholar
• Green DM, Swets JA. Signal Detection Theory and Psychophysics. New York, NY: John Wiley and Sons Inc, 1966.
   Google Scholar
• R Development Core Team. R: A Language and Environment for Statistical Computing. [Internet]. Vienna, Austria: R Foundation for Statistical Computing, 2009. Available from: http://www.R-project.org
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Charnsangavej C. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25(13):1760–1764.
   PubMed Web of Science ®Google Scholar
• Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej C. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006;26(2):481–495.
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13): 1753–1759.
   PubMed Web of Science ®Google Scholar
• Van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP, Horwich A, Huddart RA. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Brit J Cancer 2008;98(12): 1894–1902.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19(20):4054–4057.
   PubMed Web of Science ®Google Scholar
• Schutgens REG, Beckers MMJ, Haas FJLM, Biesma DH. The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 2005;90(2):214–219.
   PubMed Web of Science ®Google Scholar
• Unsal E, Atalay F, Atikcan S, Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004;98(2):93–98.
   PubMed Web of Science ®Google Scholar
• Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T, Fey MF. Coagulation markers predict survival in cancer patients. Thromb Haemost 2002;88(5):745–749.
   PubMed Web of Science ®Google Scholar
• Antoniou D, Pavlakou G, Stathopoulos GP, Karydis I, Chondrou E, Papageorgiou C, Dariotaki F, Chaimala D, Veslemes M. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer 2006;53(2):205–210.
   PubMed Web of Science ®Google Scholar
• Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prové A, Lemmens J, Vermeulen P. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002;86(3):389–395.
   PubMed Web of Science ®Google Scholar
• Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997;52(6):563–565.
   PubMed Web of Science ®Google Scholar
• Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglu E, Hatipoglu ON, Caglar T. High plasma D-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol (R Coll Radiol) 2007;19(7):494–498.
   PubMed Web of Science ®Google Scholar
• Khoury JD, Adcock DM, Chan F, Symanowski JT, Tiefenbacher S, Goodman O, Paz L, Ma Y, Ward DC, Vogelzang NJ, Fink LM. Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer. Am J Clin Pathol 2010;134(6):964–969.
   PubMed Web of Science ®Google Scholar
• Batschauer APB, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LMS, Fernandes AP, Gomez KB, Carvalho MG. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol 2009;21(6):1267–1272.
   PubMed Web of Science ®Google Scholar
• Kilic M, Yoldas O, Keskek M, Ertan T, Tez M, Gocmen E, Koc M. Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis 2008;10(3):238–241.
   PubMed Web of Science ®Google Scholar
• Koh SCL, Khalil R, Lim F-K, Ilancheran A, Choolani M. The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost 2006;12(1):3–8.
   PubMed Web of Science ®Google Scholar
• Kim HK, Song KS, Lee KR, Kang YH, Lee Y-J, Lee E-S. Comparison of plasma D-dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis. Blood Coagul Fibrinolysis 2004;15(1):9–13.
   PubMed Web of Science ®Google Scholar
• Xu G, Zhang Y-L, Huang W. Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients. World J. Gastroenterol 2004;10(6):922–923.
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Yano M, Takachi K, Kishi K, Miyashiro I, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S. Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 2006;202(1):139–145.
   PubMed Web of Science ®Google Scholar
• Blackwell K, Hurwitz H, Liebérman G, Novotny W, Snyder S, Dewhirst M, Greenberg C. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004;101(1):77–82.
   PubMed Web of Science ®Google Scholar
• Dinnes J, Hewison J, Altman DG, Deeks JJ. The basis for monitoring strategies in clinical guidelines: a case study of prostate-specific antigen for monitoring in prostate cancer. Can Med Assoc J 2011;184(2):169–177.
   Web of Science ®Google Scholar
• Rustin GJ, Van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM; MRC OV05;EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376(9747):1155–1163.
   PubMed Web of Science ®Google Scholar